OnKure Therapeutics
OKUR
52 hedge funds and large institutions have $169M invested in OnKure Therapeutics in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 3 closing their positions.
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
217% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 6
66% more capital invested
Capital invested by funds: $102M → $169M (+$66.9M)
49% more funds holding
Funds holding: 35 → 52 (+17)
9.89% more ownership
Funds ownership: 68.05% → 77.94% (+9.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$15.7M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$14.1M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.75M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$7.55M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$806K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$194K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$145K |
| 4 |
Millennium Management
New York
|
-$143K |
| 5 |
Jane Street
New York
|
-$118K |
OKUR Hedge Fund Activity: Q2 2023 in Review
52 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q2 2023, worth a combined $169M — up 66% from $102M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new OKUR positions and 3 closed out — a net gain of 17 holders — while 19 added to existing stakes and 6 trimmed.
The largest buyer was Octagon Capital Advisors, adding an estimated $15.7M. The largest seller was Novo Holdings A/S, cutting an estimated $806K.
- 52 institutional investors held OnKure Therapeutics (OKUR) as of Q2 2023, up from 35 in Q1 2023.
- Funds reported $169M of OnKure Therapeutics stock for Q2 2023, up 66% quarter-over-quarter.
- 20 funds opened new OnKure Therapeutics positions in Q2 2023 and 3 closed out, a net change of +17 holders.
- The largest OnKure Therapeutics buyer in Q2 2023 was Octagon Capital Advisors, an estimated $15.7M added.
- The largest OnKure Therapeutics seller in Q2 2023 was Novo Holdings A/S, an estimated $806K sold.
Based on aggregated 13F filings for Q2 2023.